Journal for ImmunoTherapy of Cancer (Nov 2023)

778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

  • Gino K In,
  • James Larkin,
  • Yazan Samhouri,
  • Marcus Butler,
  • Victoria Atkinson,
  • Jeffrey Chou,
  • Juan Martin-Liberal,
  • Patrick Terheyden,
  • Sajeve Thomas,
  • Wen Shi,
  • Xiao Wu,
  • Andrew S Poklepovic,
  • Young Hong,
  • Giri Sulur,
  • Friedrich Graf Finckenstein,
  • John B Haanen,
  • Andrew JS Furness,
  • Philip Lammers,
  • Ryan H Nguyen,
  • Idit Peretz

DOI
https://doi.org/10.1136/jitc-2023-SITC2023.0778
Journal volume & issue
Vol. 11, no. Suppl 1

Abstract

Read online

No abstracts available.